新型氮杂双环萘啶酮CP-99,219的体外抗菌活性
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
作者信息
Gooding B B, Jones R N
机构信息
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
出版信息
Antimicrob Agents Chemother. 1993 Feb;37(2):349-53. doi: 10.1128/AAC.37.2.349.
Abstract
CP-99,219 is a trifluoronaphthyridone with significant antibacterial activity that includes the family Enterobacteriaceae (MICs for 90% of the strains tested [MIC90s], < or = 0.015 to 0.5 micrograms/ml), Moraxella catarrhalis, Haemophilus influenzae, and gonococci (MICs, < or = 0.015 micrograms/ml). Legionella spp. were also CP-99,219 susceptible, with MICs of 0.008 to 0.12 micrograms/ml. CP-99,219 demonstrated activity greater than that of ciprofloxacin, ofloxacin, or enoxacin against Pseudomonas aeruginosa (MIC90, 1 microgram/ml), Xanthomonas maltophilia (MIC90, 2 micrograms/ml), Staphylococcus haemolyticus (MIC90, 0.5 micrograms/ml), Enterococcus faecalis (MIC90, 1 microgram/ml), and pneumococci (MIC90, 0.12 micrograms/ml). Numerous ciprofloxacin-resistant isolates were susceptible to CP-99,219, a new compound showing potential value for further in vivo trials.
摘要
CP - 99,219是一种具有显著抗菌活性的三氟萘啶酮，其抗菌谱包括肠杆菌科（90%受试菌株的最低抑菌浓度[MIC90]，≤0.015至0.5微克/毫升）、卡他莫拉菌、流感嗜血杆菌和淋球菌（MIC，≤0.015微克/毫升）。嗜肺军团菌对CP - 99,219也敏感，MIC为0.008至0.12微克/毫升。CP - 99,219对铜绿假单胞菌（MIC90，1微克/毫升）、嗜麦芽窄食单胞菌（MIC90，2微克/毫升）、溶血葡萄球菌（MIC90，0.5微克/毫升）、粪肠球菌（MIC90，1微克/毫升）和肺炎球菌（MIC90，0.12微克/毫升）的活性高于环丙沙星、氧氟沙星或依诺沙星。许多耐环丙沙星的分离株对CP - 99,219敏感，这一新型化合物显示出进一步进行体内试验的潜在价值。
相似文献
1
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.新型氮杂双环萘啶酮CP-99,219的体外抗菌活性
Antimicrob Agents Chemother. 1993 Feb;37(2):349-53. doi: 10.1128/AAC.37.2.349.
2
Antimicrobial activity of CS-940, a new trifluorinated quinolone.新型三氟喹诺酮CS-940的抗菌活性
Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30. doi: 10.1128/AAC.39.10.2325.
3
In vitro activity of BAY 12-8039, a new fluoroquinolone.新型氟喹诺酮类药物BAY 12 - 8039的体外活性
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
4
In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.新型7-(3-氮杂双环[3.1.0]己基)萘啶酮抗菌剂CP-99,219的体外活性
Diagn Microbiol Infect Dis. 1994 Aug;19(4):235-43. doi: 10.1016/0732-8893(94)90037-x.
5
In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.新型氟环丙基喹诺酮DU-6859a的体外活性
Antimicrob Agents Chemother. 1993 Dec;37(12):2747-53. doi: 10.1128/AAC.37.12.2747.
6
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.新型萘啶酮类抗菌剂CP 99,219的体外活性：与氟喹诺酮类药物的比较。
J Antimicrob Chemother. 1995 Jun;35(6):869-76. doi: 10.1093/jac/35.6.869.
7
In vitro activity of the new fluoroquinolone CP-99,219.新型氟喹诺酮CP-99,219的体外活性
Antimicrob Agents Chemother. 1994 Nov;38(11):2615-22. doi: 10.1128/AAC.38.11.2615.
8
[In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].左氧氟沙星及其他抗生素对新鲜临床分离株的体外活性
Jpn J Antibiot. 1999 Sep;52(9):571-84.
9
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.与众多其他喹诺酮类化合物相比，司帕沙星（AT - 4140、CI - 978、PD 131501）的体外抗菌活性。
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):319-30. doi: 10.1016/0732-8893(91)90023-9.
10
In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones.CP-99433与其他氟喹诺酮类药物相比的体外抗菌活性。
Diagn Microbiol Infect Dis. 1993 Jul;17(1):79-83. doi: 10.1016/0732-8893(93)90076-j.
引用本文的文献
1
Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.曲伐沙星增强了对革兰氏阴性或革兰氏阳性细菌刺激的炎症反应，导致小鼠出现中性粒细胞依赖性肝损伤。
J Pharmacol Exp Ther. 2009 Jul;330(1):72-8. doi: 10.1124/jpet.109.151068. Epub 2009 Apr 7.
2
Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.具有7-氮杂环丁烷环取代基的两种新型8-氯氟喹诺酮类化合物E-4767和E-5065的抗菌活性及药代动力学
Antimicrob Agents Chemother. 2001 Nov;45(11):3113-21. doi: 10.1128/AAC.45.11.3113-3121.2001.
3
Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.单剂量静脉注射阿拉曲沙星后，氟萘啶酮（曲伐沙星，CP 99,219）在婴幼儿和儿童中的药代动力学。
Antimicrob Agents Chemother. 2000 May;44(5):1195-9. doi: 10.1128/AAC.44.5.1195-1199.2000.
4
Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.严重社区获得性肺炎患者气道分泌物中的曲伐沙星浓度。
Antimicrob Agents Chemother. 2000 Jan;44(1):178-80. doi: 10.1128/AAC.44.1.178-180.2000.
5
Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.曲伐沙星联合万古霉素治疗兔脑膜炎模型中耐青霉素肺炎球菌的研究
Antimicrob Agents Chemother. 1999 Apr;43(4):963-5. doi: 10.1128/AAC.43.4.963.
6
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.奎奴普丁/达福普汀及新型喹诺酮类药物与庆大霉素联合应用对粪肠球菌和屎肠球菌耐药菌株的体外活性
Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):657-61. doi: 10.1007/BF01708351.
7
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.曲伐沙星与大剂量阿莫西林（每日三次，每次1g）治疗社区获得性细菌性肺炎的比较
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):447-53. doi: 10.1007/BF01691581.
8
Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.曲伐沙星和阿拉曲沙星在人体内的单剂量和多剂量给药、给药方案及药代动力学
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):427-30. doi: 10.1007/BF01691577.
9
Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.健康志愿者单次口服剂量后曲伐沙星及其代谢物的肝胆清除情况。
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):424-6. doi: 10.1007/BF01691576.
10
A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs.
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):420-3. doi: 10.1007/BF01691575.
本文引用的文献
1
In vitro and in vivo activity of DL-8280, a new oxazine derivative.新型恶嗪衍生物DL-8280的体外和体内活性
Antimicrob Agents Chemother. 1982 Oct;22(4):548-53. doi: 10.1128/AAC.22.4.548.
2
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.新型萘啶酸类似物AM - 715的体外抗菌活性
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
3
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.环丙沙星，一种对需氧菌和厌氧菌均有活性的喹诺酮羧酸化合物。
Antimicrob Agents Chemother. 1984 Mar;25(3):319-26. doi: 10.1128/AAC.25.3.319.
4
Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits.依诺沙星的体外抗菌活性评估：与其他口服吸收抗菌剂的比较、提议的纸片扩散试验解释标准及质量控制限度。
Diagn Microbiol Infect Dis. 1985 May;3(3):213-21. doi: 10.1016/0732-8893(85)90033-1.
5
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
6
Fluoroquinolone antimicrobial agents.
N Engl J Med. 1991 Feb 7;324(6):384-94. doi: 10.1056/NEJM199102073240606.
7
In vitro activity of CP-74667 compared with four other fluoroquinolones.CP-74667与其他四种氟喹诺酮类药物的体外活性比较。
Diagn Microbiol Infect Dis. 1992 Aug;15(6):531-6. doi: 10.1016/0732-8893(92)90104-2.
Zotero 插件